UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063686
Receipt number R000072890
Scientific Title A prospective observational study on the efficacy and safety of preemptive treatment (prodrome therapy) using rimegepant during the prodromal phase of migraine
Date of disclosure of the study information 2026/11/18
Last modified on 2026/11/18 23:35:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Preemptive treatment of migraine attacks using rimegepant during the prodrome

Acronym

Rimegepant Prodrome Study

Scientific Title

A prospective observational study on the efficacy and safety of preemptive treatment (prodrome therapy) using rimegepant during the prodromal phase of migraine

Scientific Title:Acronym

Prodromal Rimegepant Trial

Region

Japan


Condition

Condition

migraine

Classification by specialty

Neurology Neurosurgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to prospectively observe and evaluate the efficacy and safety of preemptive treatment (prodrome therapy) using the oral CGRP receptor antagonist rimegepant (75mg) during the prodromal phase prior to headache onset in real-world clinical practice.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Inhibition rate of moderate or severe headache within 24 hours after administration of rimegepant (75mg)

Key secondary outcomes

1. Inhibition rate of moderate or severe headache within 48 hours.
2. Pain-free rate at 24 hours.
3. Recovery rate of daily functional activities at 24 hours.
4. Incidence and severity of adverse events.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients aged 18 years or older diagnosed with migraine based on ICHD-3.
2. Patients who can clearly recognize prodromal symptoms.
3. Patients predicting >75% probability of headache onset within 1-6 hours after prodrome.
4. Patients whose prodromal treatment with rimegepant was decided by the attending physician.
5. Written informed consent obtained.

Key exclusion criteria

1. Pregnant, possibly pregnant, or lactating women.
2. Hypersensitivity to rimegepant.
3. Severe psychiatric symptoms.
4. Ineligible as judged by the investigator.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Taisyoku
Middle name
Last name Kaku

Organization

Kaku Neurosurgery Clinic

Division name

Department of Neurosurgery

Zip code

753-0066

Address

8-17 Izumi-cho, Yamaguchi-shi, Yamaguchi, 753-0066, Japan

TEL

083-920-1001

Email

kakutaisyoku@gmail.com


Public contact

Name of contact person

1st name Taisyoku
Middle name
Last name Kaku

Organization

Kaku Neurosurgery Clinic

Division name

Department of Neurosurgery

Zip code

753-0066

Address

8-17 Izumi-cho, Yamaguchi-shi, Yamaguchi, 753-0066, Japan

TEL

083-920-1001

Homepage URL


Email

kakutaisyoku@gmail.com


Sponsor or person

Institute

others

Institute

Department

Personal name



Funding Source

Organization

others

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

nstitutional Review Board for Clinical Research, Tokai University School of Medicine

Address

143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, Japan

Tel

0463-93-1121

Email

tokai-rec@tokai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 10 Month 08 Day

Date of IRB


Anticipated trial start date

2026 Year 11 Month 01 Day

Last follow-up date

2028 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a single-center, prospective observational study evaluating the efficacy and safety of preemptive treatment (prodrome therapy) using rimegepant (75 mg) during the prodromal phase of migraine in real-world clinical practice.

[Details of Observation]
1. Observational Design and Data Collection:
Targeting migraine patients whose


Management information

Registered date

2026 Year 11 Month 18 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072890